The Global Autoinjectors Market is estimated to reach over USD 226.37 billion by 2030, exhibiting a CAGR of 19.2% during the forecast period.
Autoinjectors are pen-like devices that deliver a fixed dose of medication to a patient and are meant to be self-administered. Autoinjectors are gradually becoming the gold standard in the treatment of anaphylaxis, multiple sclerosis, and rheumatoid arthritis. The majority of autoinjectors are spring-loaded, and self-injection is a simple technique. These devices can assist patients in preventing needle stick injuries and lessen needle fear. To improve the simplicity of use and alleviate the anxiety associated with self-administration of intramuscular injections, autoinjector manufacturers are focused on user-centric approaches. The autoinjector market is expected to grow significantly, given the rise in anaphylactic cases. Furthermore, firms' increased R&D efforts to create simple, cost-effective, and innovative technology-based autoinjectors for the treatment of chronic diseases such as rheumatoid arthritis and multiple sclerosis are likely to fuel market growth throughout the forecast period.
On the other hand, there are a variety of chronic conditions that necessitate daily injections. The illness's diversity, on the other hand, requires a combination of autoinjector requirements. The injection capacity, dosage, length, and thickness must be varied for each medication. Different types of autoinjectors result from these factors. The absence of appropriate autoinjectors and product variety may have a negative impact on the autoinjector business. The OEM is untrained in the production of several medications. The major players are addressing these market problems. The market is attempting to meet this problem by conducting additional research.
The Global Autoinjectors Market is segmented on the basis of type, application, and end-user. Based on type, the market is segmented into Disposable Autoinjectors and Reusable Autoinjectors. By application, the market is segmented into Rheumatoid Arthritis, Anaphylaxis, Multiple Sclerosis, and Others. By end-user, the market is segmented as home care settings and Hospitals & Clinics.
Based on application, rheumatoid arthritis is accounted as a significant contributor to the Global Autoinjectors Market.
In 2021, the market for autoinjectors was dominated by rheumatoid arthritis. The high prevalence of this group accounts for its significant share, and the rising prevalence of RA is driving up demand for autoinjectors in this treatment area. Arthritis, RA, gout, lupus, and fibromyalgia affect an estimated 20% of the total population in the United States each year.
Disposable autoinjectors segment witnessed growth at a rapid rate
The autoinjectors market is divided into two types: reusable and disposable autoinjectors. The disposable autoinjectors category held the most significant share of the worldwide autoinjectors market in 2021. Owing to their ease of use and the existence of a built-in glass syringe (which eliminates the need to load the glass syringe manually), disposable autoinjectors are the most popular autoinjectors among patients with poor dexterity or visual impairments.
In the region, the North America Global Autoinjectors Market holds a significant revenue share.
The Asia Pacific market is expected to outperform other regional players during the projected period. In this area, autoinjectors are in high demand. The rising number of diabetics is driving up demand for the product. Furthermore, the healthcare infrastructure is growing at a breakneck speed, and it leads to an increase in the production of autoinjectors. In this region, home care and self-administration of chronic conditions rise. Many patients and their families learn to use autoinjectors for non-urgent situations. The existence of leading autoinjector firms is beneficial to market growth. In the Asia-Pacific area, autoinjectors are constantly evolving and in high demand. Furthermore, an increase in the occurrences of anaphylaxis, rheumatoid arthritis, and other disorders such as anaemia and migraine and future technological developments by firms are likely to propel the market forward.
To keep and grow their customer base, key players are focusing on portable and user-friendly auto-injectors. To protect their brand equity, companies like Mylan N.V. and Eli Lilly and Company are focusing more on user-friendly auto-injectors. New entrants are concentrating their efforts on reaching emerging markets by introducing low-cost auto-injector devices. Some businesses, such as Mylan N.V., Teva Pharmaceuticals, and others, are launching generic versions of cost-effective auto-injectors devices and targeting emerging markets, such as Asia-Pacific, the Middle East, and others, in order to stay competitive and grow in the global Auto-Injectors Market. Some of the key players featured in the auto-injectors market are, Amgen Inc., Antares Pharma, Becton, Dickinson, And Company (BD), ELI LILLY AND COMPANY, Johnson & Johnson, MYLAN N.V., Novartis AG, SHL MEDICAL AG, TEVA Pharmaceutical Industries LTD., YPSOMED AG, ATS Automation Tooling Systems Inc. Owen Mumford Ltd., SHL Group, Oval Medical Technologies Ltd., E3D Elcam Drug Delivery Devices, kaleo, Inc., Crossject, Gerresheimer AG.